Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC plus systemic chemotherapy for peritoneal metastatic pancreatic cancer (Phase II)
ChiCTR2500100124Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, paclitaxel and gemcitabine in pancreatic cancer (PC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: 1-year overall survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
cisplatinpaclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500100124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100124.